Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
- PMID: 33046870
- DOI: 10.1038/s41591-020-1085-z
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
Abstract
Preoperative immunotherapy with anti-PD1 plus anti-CTLA4 antibodies has shown remarkable pathological responses in melanoma1 and colorectal cancer2. In NABUCCO (ClinicalTrials.gov: NCT03387761 ), a single-arm feasibility trial, 24 patients with stage III urothelial cancer (UC) received two doses of ipilimumab and two doses of nivolumab, followed by resection. The primary endpoint was feasibility to resect within 12 weeks from treatment start. All patients were evaluable for the study endpoints and underwent resection, 23 (96%) within 12 weeks. Grade 3-4 immune-related adverse events occurred in 55% of patients and in 41% of patients when excluding clinically insignificant laboratory abnormalities. Eleven patients (46%) had a pathological complete response (pCR), meeting the secondary efficacy endpoint. Fourteen patients (58%) had no remaining invasive disease (pCR or pTisN0/pTaN0). In contrast to studies with anti-PD1/PD-L1 monotherapy, complete response to ipilimumab plus nivolumab was independent of baseline CD8+ presence or T-effector signatures. Induction of tertiary lymphoid structures upon treatment was observed in responding patients. Our data indicate that combined CTLA-4 plus PD-1 blockade might provide an effective preoperative treatment strategy in locoregionally advanced UC, irrespective of pre-existing CD8+ T cell activity.
Comment in
-
Neoadjuvant anti-CTLA4 and anti-PD1 blockade in advanced urothelial cancer.Nat Rev Urol. 2020 Dec;17(12):658. doi: 10.1038/s41585-020-00399-0. Nat Rev Urol. 2020. PMID: 33173210 No abstract available.
Similar articles
-
Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.J Dermatol. 2019 Jun;46(6):498-506. doi: 10.1111/1346-8138.14865. Epub 2019 Apr 4. J Dermatol. 2019. PMID: 30945333
-
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.Lancet Oncol. 2019 Jul;20(7):948-960. doi: 10.1016/S1470-2045(19)30151-2. Epub 2019 May 31. Lancet Oncol. 2019. PMID: 31160251 Clinical Trial.
-
Nivolumab plus ipilimumab in advanced melanoma.N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2. N Engl J Med. 2013. PMID: 23724867 Free PMC article. Clinical Trial.
-
Combination therapy with PD-1 or PD-L1 inhibitors for cancer.Int J Clin Oncol. 2020 May;25(5):818-830. doi: 10.1007/s10147-019-01548-1. Epub 2019 Sep 23. Int J Clin Oncol. 2020. PMID: 31549270 Review.
-
The next generation of immunotherapy: keeping lung cancer in check.J Hematol Oncol. 2017 Apr 24;10(1):87. doi: 10.1186/s13045-017-0456-5. J Hematol Oncol. 2017. PMID: 28434399 Free PMC article. Review.
Cited by
-
Tertiary lymphoid structures as unique constructions associated with the organization, education, and function of tumor-infiltrating immunocytes.J Zhejiang Univ Sci B. 2022 Oct 15;23(10):812-822. doi: 10.1631/jzus.B2200174. J Zhejiang Univ Sci B. 2022. PMID: 36226536 Free PMC article.
-
Efficacy and safety of the first-line systemic treatments in patients with advanced-stage urothelial carcinoma: a systematic review and network meta-analysis.Front Oncol. 2024 Sep 16;14:1468784. doi: 10.3389/fonc.2024.1468784. eCollection 2024. Front Oncol. 2024. PMID: 39351347 Free PMC article.
-
The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma.Hum Vaccin Immunother. 2023 Dec 31;19(1):2178217. doi: 10.1080/21645515.2023.2178217. Epub 2023 Feb 12. Hum Vaccin Immunother. 2023. PMID: 36775257 Free PMC article. Review.
-
Tertiary lymphoid structures are critical for cancer prognosis and therapeutic response.Front Immunol. 2023 Jan 11;13:1063711. doi: 10.3389/fimmu.2022.1063711. eCollection 2022. Front Immunol. 2023. PMID: 36713409 Free PMC article. Review.
-
Role of tertiary lymphoid organs in the regulation of immune responses in the periphery.Cell Mol Life Sci. 2022 Jun 11;79(7):359. doi: 10.1007/s00018-022-04388-x. Cell Mol Life Sci. 2022. PMID: 35689679 Free PMC article. Review.
References
-
- Rozeman, E. A. et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 20, 948–960 (2019).
-
- Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566–576 (2020).
-
- Stein, J. P. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19, 666–675 (2001). - DOI
-
- Zargar, H. et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur. Urol. 67, 241–249 (2014).
-
- Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur. Urol. 48, 202–205 (2005). - DOI
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials